BiotechTube

BIIB074 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Inherited Erythromelalgia

Conditions

Primary Inherited Erythromelalgia

Trial Timeline

Sep 9, 2016 → Jan 5, 2017

NCT ID
NCT02917187

About BIIB074 + Placebo

BIIB074 + Placebo is a phase 2 stage product being developed by Biogen for Primary Inherited Erythromelalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02917187. Target conditions include Primary Inherited Erythromelalgia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT03070132Phase 3Withdrawn
NCT03637387Phase 3Withdrawn
NCT03339336Phase 2Terminated
NCT02935608Phase 2Completed
NCT02917187Phase 2Completed
NCT02831517Phase 1Completed

Competing Products

20 competing products in Primary Inherited Erythromelalgia

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
22
azenosertibZentalis PharmaceuticalsPhase 2
44
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
REN001OnKure TherapeuticsPhase 1
25
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
44
REN001OnKure TherapeuticsPhase 2/3
57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
Rituximab, lenalidomideCelltrionPhase 2
52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPre-clinical
23
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
23
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
23
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
Roxadustat + PlaceboAstellas PharmaPhase 3
77
Enzalutamide + ExemestaneAstellas PharmaPhase 2
52
Bocidelpar + PlaceboAstellas PharmaPhase 2
52
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82